{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:57:23Z","timestamp":1777431443126,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"DOI":"10.1186\/s12955-024-02287-2","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T01:01:58Z","timestamp":1725238918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cataloging health state utility estimates for Duchenne muscular dystrophy and related conditions"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-1111","authenticated-orcid":false,"given":"Lauren A.","family":"Do","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren E.","family":"Sedita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa C.","family":"Klimchak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"2287_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77\u201393.","journal-title":"Lancet Neurol"},{"key":"2287_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9:177\u201389.","journal-title":"Lancet Neurol"},{"key":"2287_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.23528","volume":"71","author":"JR Mendell","year":"2012","unstructured":"Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, Kneile K, Dunn DM, Duval B, Aoyagi A, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71:304\u201313.","journal-title":"Ann Neurol"},{"key":"2287_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s11136-019-02355-x","volume":"29","author":"SM Szabo","year":"2020","unstructured":"Szabo SM, Audhya IF, Malone DC, Feeny D, Gooch KL. Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review. Qual Life Res. 2020;29:593\u2013605.","journal-title":"Qual Life Res"},{"key":"2287_CR5","doi-asserted-by":"crossref","unstructured":"Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifir\u00f2 G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis. 2020;15:141.","DOI":"10.1186\/s13023-020-01430-8"},{"key":"2287_CR6","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr., Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51:919\u201328.","journal-title":"Cell"},{"key":"2287_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejpn.2011.07.001","volume":"16","author":"V Humbertclaude","year":"2012","unstructured":"Humbertclaude V, Hamroun D, Bezzou K, Berard C, Boespflug-Tanguy O, Bommelaer C, Campana-Salort E, Cances C, Chabrol B, Commare MC, et al. Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. Eur J Paediatr Neurol. 2012;16:149\u201360.","journal-title":"Eur J Paediatr Neurol"},{"key":"2287_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/00207454.2020.1740218","volume":"131","author":"A Salmaninejad","year":"2021","unstructured":"Salmaninejad A, Jafari Abarghan Y, Bozorg Qomi S, Bayat H, Yousefi M, Azhdari S, Talebi S, Mojarrad M. Common therapeutic advances for Duchenne muscular dystrophy (DMD). Int J Neurosci. 2021;131:370\u201389.","journal-title":"Int J Neurosci"},{"key":"2287_CR9","doi-asserted-by":"publisher","first-page":"e2304","DOI":"10.1212\/WNL.0000000000012910","volume":"97","author":"J Broomfield","year":"2021","unstructured":"Broomfield J, Hill M, Guglieri M, Crowther M, Abrams K. Life Expectancy in Duchenne muscular dystrophy: reproduced individual Patient Data Meta-analysis. Neurology. 2021;97:e2304\u201314.","journal-title":"Neurology"},{"key":"2287_CR10","unstructured":"US Food and Drug Administration. VYONDYS 53 (golodirsen) injection, for intravenous use. Prescribing Information ed.; 2019."},{"key":"2287_CR11","unstructured":"US Food and Drug Administration. EXONDYS 51 (eteplirsen) injection, for intravenous use. Prescribing Information ed.; 2019."},{"key":"2287_CR12","unstructured":"US Food and Drug Administration. VILTEPSO (viltolarsen) injection, for intravenous use. Prescribing Information ed.; 2019."},{"key":"2287_CR13","unstructured":"US Food and Drug Administration. AMONDYS 45 (casimersen) injection, for intravenous use. Prescribing Information ed.; 2021."},{"key":"2287_CR14","unstructured":"US Food and Drug Administration. ELEVIDYS (delandistrogene moxeparvovec-rokl) suspension, for intravenous use. Prescribing Information ed.; 2024."},{"key":"2287_CR15","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/0277-9536(95)00112-K","volume":"41","author":"The World Health Organization Quality of Life assessment (WHOQOL)","year":"1995","unstructured":"The World Health Organization Quality of Life assessment (WHOQOL). Position paper from the World Health Organization. Soc Sci Med. 1995;41:1403\u20139.","journal-title":"Soc Sci Med"},{"key":"2287_CR16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/dmcn.12938","volume":"58","author":"E Landfeldt","year":"2016","unstructured":"Landfeldt E, Lindgren P, Bell CF, Guglieri M, Straub V, Lochmuller H, Bushby K. Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study. Dev Med Child Neurol. 2016;58:508\u201315.","journal-title":"Dev Med Child Neurol"},{"key":"2287_CR17","doi-asserted-by":"crossref","unstructured":"Neumann PJGT, Russell LB, Sanders GD, Siegel JE. Second panel on cost-effectiveness in Health and Medicine. Oxford University Press; 2016.","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001"},{"key":"2287_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-1-54","volume":"1","author":"J Horsman","year":"2003","unstructured":"Horsman J, Furlong W, Feeny D, Torrance G. The Health utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.","journal-title":"Health Qual Life Outcomes"},{"key":"2287_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMp1612619","volume":"376","author":"PJ Neumann","year":"2017","unstructured":"Neumann PJ, Sanders GD. Cost-effectiveness analysis 2.0. N Engl J Med. 2017;376:203\u20135.","journal-title":"N Engl J Med"},{"key":"2287_CR20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, et al. Recommendations for Conduct, Methodological Practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in Health and Medicine. JAMA. 2016;316:1093\u2013103.","journal-title":"JAMA"},{"key":"2287_CR21","unstructured":"Cost-Effectivness. Analysis Registry [www.cearegistry.org ]."},{"key":"2287_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jpeds.2009.03.007","volume":"155","author":"LA Prosser","year":"2009","unstructured":"Prosser LA. Current challenges and future research in measuring preferences for pediatric health outcomes. J Pediatr. 2009;155:7\u20139.","journal-title":"J Pediatr"},{"key":"2287_CR23","doi-asserted-by":"publisher","first-page":"e0135672","DOI":"10.1371\/journal.pone.0135672","volume":"10","author":"D Thorrington","year":"2015","unstructured":"Thorrington D, Eames K. Measuring Health Utilities in Children and adolescents: a systematic review of the literature. PLoS ONE. 2015;10:e0135672.","journal-title":"PLoS ONE"},{"key":"2287_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, Jain M, Kleijnen J. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12:79.","journal-title":"Orphanet J Rare Dis"},{"key":"2287_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","volume":"83","author":"E Landfeldt","year":"2014","unstructured":"Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, Lochmuller H, Bushby K. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83:529\u201336.","journal-title":"Neurology"},{"key":"2287_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3109\/07853890109002088","volume":"33","author":"M Drummond","year":"2001","unstructured":"Drummond M. Introducing economic and quality of life measurements into clinical studies. Ann Med. 2001;33:344\u20139.","journal-title":"Ann Med"},{"key":"2287_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1081\/COPD-200052090","volume":"2","author":"RM Kaplan","year":"2005","unstructured":"Kaplan RM. The minimally clinically important difference in generic utility-based measures. COPD. 2005;2:91\u20137.","journal-title":"COPD"},{"key":"2287_CR28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/mds.27587","volume":"34","author":"C Li","year":"2019","unstructured":"Li C, Gajic-Veljanoski O, Schaink AK, Higgins C, Fasano A, Sikich N, Dhalla I, Ng V. Cost-effectiveness of magnetic resonance-guided focused Ultrasound for essential tremor. Mov Disord. 2019;34:735\u201343.","journal-title":"Mov Disord"},{"key":"2287_CR29","volume-title":"Stata Statistical Software: release 15. College Station","author":"StataCorp","year":"2017","unstructured":"StataCorp. Stata Statistical Software: release 15. College Station. TX: StataCorp LLC; 2017."},{"key":"2287_CR30","unstructured":"Microsoft Corporation. Microsoft Excel. Retrieved from https:\/\/office.microsoft.com\/excel. 2013."},{"key":"2287_CR31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12891-022-05504-5","volume":"23","author":"A Kim","year":"2022","unstructured":"Kim A, Park M, Shin HI. Pain characteristics among individuals with Duchenne muscular dystrophy according to their clinical stage. BMC Musculoskelet Disord. 2022;23:536.","journal-title":"BMC Musculoskelet Disord"},{"key":"2287_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","volume":"38","author":"TO Tengs","year":"2000","unstructured":"Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38:583\u2013637.","journal-title":"Med Care"},{"key":"2287_CR33","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1080\/13696998.2022.2090152","volume":"25","author":"LL Freath","year":"2022","unstructured":"Freath LL, Curry AS, Cork DMW, Audhya IF, Gooch KL. QALYs and ambulatory status: societal preferences for healthcare decision making. J Med Econ. 2022;25:888\u201393.","journal-title":"J Med Econ"},{"key":"2287_CR34","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s00415-016-8080-9","volume":"263","author":"E Landfeldt","year":"2016","unstructured":"Landfeldt E, Lindgren P, Bell CF, Guglieri M, Straub V, Lochmuller H, Bushby K. Quantifying the burden of caregiving in Duchenne muscular dystrophy. J Neurol. 2016;263:906\u201315.","journal-title":"J Neurol"},{"key":"2287_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.apmr.2006.12.032","volume":"88","author":"CE Schwartz","year":"2007","unstructured":"Schwartz CE, Andresen EM, Nosek MA, Krahn GL, Measurement REPHS. Response shift theory: important implications for measuring quality of life in people with disability. Arch Phys Med Rehabil. 2007;88:529\u201336.","journal-title":"Arch Phys Med Rehabil"},{"key":"2287_CR36","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1007\/s11136-021-02846-w","volume":"30","author":"A Vanier","year":"2021","unstructured":"Vanier A, Oort FJ, McClimans L, Ow N, Gulek BG, Bohnke JR, Sprangers M, Sebille V, Mayo N. Response shift - in Sync Working G: response shift in patient-reported outcomes: definition, theory, and a revised model. Qual Life Res. 2021;30:3309\u201322.","journal-title":"Qual Life Res"},{"key":"2287_CR37","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/hec.4131","volume":"29","author":"SA Lipman","year":"2020","unstructured":"Lipman SA, Brouwer WBF, Attema AE. What is it going to be, TTO or SG? A direct test of the validity of health state valuation. Health Econ. 2020;29:1475\u201381.","journal-title":"Health Econ"},{"key":"2287_CR38","doi-asserted-by":"publisher","first-page":"690","DOI":"10.5535\/arm.2018.42.5.690","volume":"42","author":"J Kim","year":"2018","unstructured":"Kim J, Jung IY, Kim SJ, Lee JY, Park SK, Shin HI, Bang MS. A New Functional Scale and Ambulatory Functional classification of Duchenne muscular dystrophy: Scale Development and preliminary analyses of reliability and validity. Ann Rehabil Med. 2018;42:690\u2013701.","journal-title":"Ann Rehabil Med"},{"key":"2287_CR39","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.nmd.2016.05.016","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ, Group DMDI, Trajectory Analysis P. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2016;26:576\u201383.","journal-title":"Neuromuscul Disord"},{"key":"2287_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/0168-8510(96)00814-7","volume":"36","author":"F Rutten","year":"1996","unstructured":"Rutten F. Economic evaluation and health care decision-making. Health Policy. 1996;36:215\u201329.","journal-title":"Health Policy"},{"key":"2287_CR41","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00019053-200826090-00007","volume":"26","author":"J Brazier","year":"2008","unstructured":"Brazier J. Valuing health states for use in cost-effectiveness analysis. PharmacoEconomics. 2008;26:769\u201379.","journal-title":"PharmacoEconomics"},{"key":"2287_CR42","doi-asserted-by":"publisher","first-page":"1717030","DOI":"10.1080\/20016689.2020.1717030","volume":"8","author":"JA McDougall","year":"2020","unstructured":"McDougall JA, Furnback WE, Wang BCM, Mahlich J. Understanding the global measurement of willingness to pay in health. J Mark Access Health Policy. 2020;8:1717030.","journal-title":"J Mark Access Health Policy"},{"key":"2287_CR43","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.healthpol.2018.04.001","volume":"122","author":"VT Reckers-Droog","year":"2018","unstructured":"Reckers-Droog VT, van Exel NJA, Brouwer WBF. Looking back and moving forward: on the application of proportional shortfall in healthcare priority setting in the Netherlands. Health Policy. 2018;122:621\u20139.","journal-title":"Health Policy"},{"key":"2287_CR44","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.healthpol.2016.01.012","volume":"120","author":"T Ottersen","year":"2016","unstructured":"Ottersen T, Forde R, Kakad M, Kjellevold A, Melberg HO, Moen A, Ringard A, Norheim OF. A new proposal for priority setting in Norway: open and fair. Health Policy. 2016;120:246\u201351.","journal-title":"Health Policy"},{"key":"2287_CR45","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jval.2020.10.003","volume":"24","author":"DN Lakdawalla","year":"2021","unstructured":"Lakdawalla DN, Phelps CE. Health Technology Assessment with diminishing returns to Health: the generalized risk-adjusted cost-effectiveness (GRACE) Approach. Value Health. 2021;24:244\u20139.","journal-title":"Value Health"},{"key":"2287_CR46","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1023\/A:1025170308141","volume":"12","author":"RP Insinga","year":"2003","unstructured":"Insinga RP, Fryback DG. Understanding differences between self-ratings and population ratings for health in the EuroQOL. Qual Life Res. 2003;12:611\u20139.","journal-title":"Qual Life Res"},{"key":"2287_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/1099-1050(200101)10:1<27::AID-HEC561>3.0.CO;2-R","volume":"10","author":"D Polsky","year":"2001","unstructured":"Polsky D, Willke RJ, Scott K, Schulman KA, Glick HA. A comparison of scoring weights for the EuroQol derived from patients and the general public. Health Econ. 2001;10:27\u201337.","journal-title":"Health Econ"},{"key":"2287_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1477-7525-12-21","volume":"12","author":"R Wilson","year":"2014","unstructured":"Wilson R, Hansen P, Langley J, Derrett S. A comparison of injured patient and general population valuations of EQ-5D health states for New Zealand. Health Qual Life Outcomes. 2014;12:21.","journal-title":"Health Qual Life Outcomes"},{"key":"2287_CR49","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s41687-023-00671-y","volume":"7","author":"IF Audhya","year":"2023","unstructured":"Audhya IF, Szabo SM, Bever A, O\u2019Sullivan F, Malone DC, Feeny D, Neumann P, Iannaccone ST, Jayasinghe P, Gooch KL. Estimating health state utilities in Duchenne muscular dystrophy using the health utilities index and EQ-5D-5L. J Patient Rep Outcomes. 2023;7:132.","journal-title":"J Patient Rep Outcomes"},{"key":"2287_CR50","doi-asserted-by":"publisher","first-page":"1183101","DOI":"10.3389\/fphys.2023.1183101","volume":"14","author":"A Bez Batti Angulski","year":"2023","unstructured":"Bez Batti Angulski A, Hosny N, Cohen H, Martin AA, Hahn D, Bauer J, Metzger JM. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front Physiol. 2023;14:1183101.","journal-title":"Front Physiol"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-024-02287-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-024-02287-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-024-02287-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T13:15:22Z","timestamp":1725282922000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-024-02287-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2287"],"URL":"https:\/\/doi.org\/10.1186\/s12955-024-02287-2","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"At the time of the study,\u00a0Lauren Do and David Kim were affiliated with the Cost-Effectiveness Analysis Registry that receives unrestricted sponsorships from a number of government, private foundation and pharmaceutical industry sponsors (full list is available at ). Lauren Sedita, Alexa Klimchak, and Rachel Salazar are employees of Sarepta Therapeutics, Inc and may hold stock\/options.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"72"}}